Result for
Tag: treatment
June 14, 2021
COVID-19 Treatment Combinations and Associations with Mortality in a Large Multi-Site Healthcare System
A study conducted between March and July 2020 that assessed the association between COVID-19 mortality and different treatment combinations found that anticoagulation treatment alone was associated with significantly reduced mortality for both patients receiving intensive care and non-intensive care. The four treatment combinations studied were anticoagulation only (OR=0.2), anticoagulation and remdesivir (OR=0.3), anticoagulation and corticosteroids…
June 11, 2021
Improved Survival among Hospitalized Patients with COVID-19 Treated with Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study
A retrospective cohort study from Denmark found that patients hospitalized with COVID-19 (N=2,747) who were treated with remdesivir and dexamethasone had lower odds of 30-day mortality (OR=0.47) and progression to mechanical ventilation (OR=0.36) compared to persons receiving the standard of care. However, the authors caution that because treatment was not randomized, study data does not…
June 8, 2021
Nanobodies from Camelid Mice and Llamas Neutralize SARS-CoV-2 Variants
Two groups of single-domain antibodies, known as nanobodies, isolated from llamas and genetically engineered mice was identified to possess anti-SARS-CoV-2 receptor binding domain (RBD) neutralizing activity. The first group is able to bind to a region in the RBD largely preserved across SARS-CoV-2 mutations but rarely targeted by human antibodies, while the second group demonstrated…
June 7, 2021
Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients with COVID-19
Treatment with monoclonal antibody (mAb) therapy, including casirivimab/imdevimab and bamlanivimab, was associated with a significant reduction in the frequency of hospitalization compared to controls not receiving mAb treatment (1.7% vs. 24%) in a retrospective study of 617 outpatients with COVID-19 classified as high-risk (n = 175 received mAb). There were no COVID-19-related deaths in the…
June 4, 2021
Inhaled Corticosteroids Do Not Adversely Impact Outcomes in COVID-19 Positive Patients with COPD: An Analysis of Cleveland Clinic’s COVID-19 Registry
A large retrospective cohort study of persons with chronic obstructive pulmonary disease (COPD) (N=27,810) found that inhaled corticosteroid therapy did not increase COVID-19 related healthcare utilization or mortality. There were no statistically significant differences observed in hospitalization, ICU admission, endotracheal intubation, mechanical ventilation, or mortality among persons with a positive SARS-COV-2 test after adjusting for…
Nasal Delivery of an IgM Offers Broad Protection from SARS-CoV-2 Variants
A novel, engineered immunoglobulin M (IgM) intranasally delivered neutralizing antibody demonstrated superior neutralizing activity against multiple SARS-CoV-2 variants in mice, including B.1.1.7 (Delta), P.1 (Gamma), and B.1.351 (Beta). The IgM antibody therapy was >230-fold more potent in reducing SARS-CoV-2 lung viral load than IgG neutralizing antibodies currently in use, to which variants of concern are…
June 3, 2021
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities
Preventive treatment with the monoclonal antibody bamlanivimab reduced the risk of COVID-19 among residents and staff of skilled nursing facilities (n=966) who were negative for SARS-CoV-2 infection and seronegative at baseline in a randomized trial (8.5% vs 15.2%, OR=0.43 95% CI 0.28-0.68). All 5 deaths occurred in residents randomized to receive placebo. Participants were enrolled…
June 1, 2021
Colchicine for Community-Treated Patients with COVID-19 (COLCORONA): A Phase 3, Randomised, Double-Blinded, Adaptive, Placebo-Controlled, Multicentre Trial
The anti-inflammatory drug colchicine did not change the rate of hospital admission or death related to COVID-19 (a composite endpoint) in a phase 3 double-blind placebo-controlled trial among non-hospitalized patients diagnosed with COVID-19 either by PCR testing or clinical criteria (OR=0.79, 95%CI: 0.61-1.03). The primary endpoint occurred in 4.7% (104 of 2,235) patients in the…
May 26, 2021
Monoclonal Antibody Treatment Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread
[Pre-print, not peer-reviewed] A modeling study of SARS-CoV-2 transmission in the US population found that allocating monoclonal antibodies (mAbs) as post-exposure prophylaxis (PEP) and treatment of persons with COVID-19 in combination with a vaccination program could substantially reduce infections and mortality. Allocation of mAbs as PEP to persons >65 years of age averted up to…
Ivermectin for the Treatment of COVID-19 A Systematic Review and Meta-Analysis of Randomized Controlled Trials
[Pre-print, not peer-reviewed] A systematic review and meta-analysis (n = 10 studies, n = 1,173 patients) of randomized controlled trials found that the use of ivermectin for treatment of COVID-19 did not reduce all-cause mortality, length of hospitalization, adverse events, or viral clearance. Trials of ivermectin for the treatment of mild to moderate COVID-19 in…
Next page